CCCEH Meeting: Next Steps

1. Follow-up: Value Added Information
   a. New Data/Information:
      i. Follow-up NYC/DOH "linked" data set – utility dose-reconstruction
      ii. Formally request R. Whyatt to review "greyed out" pesticide product data from questionnaire – request these data and/or summary data if useful
      iii. Evaluate comparability Pb:CPF re: neurodevelopmental manifestations and MRI brain images
         1. Consult "expert" (Basser?)
      iv. Follow-up Hattis PBPK publication to <u>Risk Analysis</u>
   b. New Analyses of Available Data:
      i. Formally request analysis using age of housing as a lead surrogate
      ii. "Growth Curve" Analysis – pseudo-longitudinal analysis – utility?
      iii. Request cont/cat OP analysis- residual confounding –utility?
      iv. Inferential analysis – ave IQ by CPF cat –utility?
      v. Secular change: Request stratified analysis pre-/post-2000, PAH on ND (as compared CPF)- utility?
2. Obtain Available Studies/Information to inform question
   a. Whyatt and Bradman 2006 – CHS review of environmental measures in childhood
   b. Rauh and Arunajadai 2012– extrapolation <LOD
   c. FIFRA SAP 2008 – meeting transcript, qualification of ND test administrators
3. Dead-Ends:
   a. Imputation techniques assuming non-random missingness for post-natal 7-year blood lead values in CPF high exposure group
      i. %<LOD blood lead in low CPF exposure group too great to support robust extrapolation
   b. No repeat exposure measures available – cannot quantitatively evaluate "shift in exposure" over time
   c. Sample size too small for "mixtures" analysis